TPD & Induced Proximity Summit Leaderboard
  • Tuesday, June 23, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 83

Author

Pharma Journalist 8887 posts 0 comments

Opus Genetics’ OPGx-LCA5 Gene Therapy Earns FDA RMAT Designation

May 8, 2025
Opus Genetics, Inc. a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders,…
Read More...

BioVaxys and Sona Nanotech Enter Research Collaboration

May 8, 2025
BioVaxys Technology Corp. and Sona Nanotech Inc. have announced a research collaboration to develop innovative cancer therapeutics by combining BioVaxys' DPX immune-educating platform…
Read More...

Speaker Interview with Anna Karmann, Chief Medical Officer, AdvanCell

May 6, 2025
AdvanCell has amassed a great amount of funding recently from $18M in Federal Funding just this week and $112M Series C Financing. What led such financing? We received non-dilutive…
Read More...

FDA Grants Fast Track for Alterity’s ATH434 in Multiple System Atrophy Treatment

May 6, 2025
Alterity Therapeutics has received Fast Track designation from the FDA for its investigational drug, ATH434, as a potential treatment for Multiple System Atrophy (MSA), a…
Read More...

Oral Semaglutide 25 mg Filing Accepted by FDA; Could Be First Oral GLP-1 for Obesity

May 6, 2025
Novo Nordisk has announced that the FDA has accepted the New Drug Application (NDA) for a once-daily 25 mg oral formulation of Wegovy (semaglutide) for chronic weight management in…
Read More...

TAE Life Sciences and Ohio State Partner on Boron Drug Innovation for Cancer Therapy

May 6, 2025
TAE Life Sciences and The Ohio State University Comprehensive Cancer Center have announced a landmark collaboration focused on advancing boron-based drug innovation for Boron Neutron…
Read More...

Teva and Alvotech Gain FDA Interchangeability for SELARSDI Biosimilar to Stelara

May 6, 2025
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Alvotech announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI™…
Read More...

VERAXA and OmniAb Partner to Develop Novel Bispecific Antibody-Drug Conjugate

May 6, 2025
VERAXA Biotech AG, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp., announced a co-discovery alliance with…
Read More...

Illumina & Ovation.io Launch Novel GLP-1 Dataset for Faster Therapy Development

May 6, 2025
Illumina and Ovation.io have announced a groundbreaking collaboration to create the largest commercially available clinical multiomic dataset from 25,000 patients treated with GLP-1…
Read More...

FDA Approves Johnson & Johnson’s IMAAVY for Broad Generalized Myasthenia Gravis…

May 5, 2025
Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab-aahu), a novel human monoclonal antibody that blocks the neonatal…
Read More...
Prev Next
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
In Vivo Cell Engineering & Gene Editing Summit
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Voro and Alloy Partner on Safer Cancer Immunotherapies
  • uniQure Reports Early Promise for Epilepsy Gene Therapy
  • Boltz and Takeda Expand AI-Powered Drug Discovery Efforts
  • SK Pharmteco Partners With OTXL for Rare Disease Therapies
  • Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.